Cargando…
Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung cancer. H...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807326/ https://www.ncbi.nlm.nih.gov/pubmed/34904383 http://dx.doi.org/10.1111/1759-7714.14267 |
_version_ | 1784643643257126912 |
---|---|
author | Ito, Takashi Nagashima, Hiromi Akiyama, Masachika Utsumi, Yu Sato, Hideomi Chiba, Shinji Sugai, Mayu Ube, Kenji Mori, Yoshiaki Watanabe, Kana Fukuhara, Tatsuro Maemondo, Makoto |
author_facet | Ito, Takashi Nagashima, Hiromi Akiyama, Masachika Utsumi, Yu Sato, Hideomi Chiba, Shinji Sugai, Mayu Ube, Kenji Mori, Yoshiaki Watanabe, Kana Fukuhara, Tatsuro Maemondo, Makoto |
author_sort | Ito, Takashi |
collection | PubMed |
description | BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung cancer. However, it is known that ICIs have poorer efficacy in EGFR‐mutated NSCLC. METHODS: We collected data for patients with EGFR‐mutated NSCLC receiving monotherapy with ICIs after EGFR‐TKIs between December 2015 and March 2020 in three institutions, and retrospectively analyzed the association between patient characteristics and efficacy of ICIs. RESULTS: A total of 25 patients were included in this study. We defined responders as patients undergoing 90 days or longer of ICI treatment. Comparing characteristics between responders and non‐responders, more tumors with L858R EGFR mutation were observed in responders than in non‐responders (L858R: 66.7% and 25.0%, respectively, p < 0.05). There was no difference in incidence of T790M resistance mutation before ICI treatment. The PD‐L1 positive rate was slightly higher in responders but not statistically significant (22.2% and 12.5%, respectively). Median duration of EGFR‐TKI pretreatment was shorter in ICI responders compared with nonresponders (13.3 and 19.9 months, respectively). The survival of patients with L858R tumors was significantly longer than that of patients with exon 19 deletion (HR: 0.35, 95% CI: 0.13–0.93, p = 0.026). CONCLUSIONS: ICI treatment tends to have better efficacy in patients with L858R‐mutated tumors. This study suggests that patients with L858R‐mutated NSCLC are candidates for ICI treatment after EGFR‐TKI treatment. |
format | Online Article Text |
id | pubmed-8807326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-88073262022-02-04 Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer Ito, Takashi Nagashima, Hiromi Akiyama, Masachika Utsumi, Yu Sato, Hideomi Chiba, Shinji Sugai, Mayu Ube, Kenji Mori, Yoshiaki Watanabe, Kana Fukuhara, Tatsuro Maemondo, Makoto Thorac Cancer Original Articles BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung cancer. However, it is known that ICIs have poorer efficacy in EGFR‐mutated NSCLC. METHODS: We collected data for patients with EGFR‐mutated NSCLC receiving monotherapy with ICIs after EGFR‐TKIs between December 2015 and March 2020 in three institutions, and retrospectively analyzed the association between patient characteristics and efficacy of ICIs. RESULTS: A total of 25 patients were included in this study. We defined responders as patients undergoing 90 days or longer of ICI treatment. Comparing characteristics between responders and non‐responders, more tumors with L858R EGFR mutation were observed in responders than in non‐responders (L858R: 66.7% and 25.0%, respectively, p < 0.05). There was no difference in incidence of T790M resistance mutation before ICI treatment. The PD‐L1 positive rate was slightly higher in responders but not statistically significant (22.2% and 12.5%, respectively). Median duration of EGFR‐TKI pretreatment was shorter in ICI responders compared with nonresponders (13.3 and 19.9 months, respectively). The survival of patients with L858R tumors was significantly longer than that of patients with exon 19 deletion (HR: 0.35, 95% CI: 0.13–0.93, p = 0.026). CONCLUSIONS: ICI treatment tends to have better efficacy in patients with L858R‐mutated tumors. This study suggests that patients with L858R‐mutated NSCLC are candidates for ICI treatment after EGFR‐TKI treatment. John Wiley & Sons Australia, Ltd 2021-12-13 2022-02 /pmc/articles/PMC8807326/ /pubmed/34904383 http://dx.doi.org/10.1111/1759-7714.14267 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ito, Takashi Nagashima, Hiromi Akiyama, Masachika Utsumi, Yu Sato, Hideomi Chiba, Shinji Sugai, Mayu Ube, Kenji Mori, Yoshiaki Watanabe, Kana Fukuhara, Tatsuro Maemondo, Makoto Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer |
title | Treatment with immune checkpoint inhibitors after EGFR‐TKIs in
EGFR
‐mutated lung cancer |
title_full | Treatment with immune checkpoint inhibitors after EGFR‐TKIs in
EGFR
‐mutated lung cancer |
title_fullStr | Treatment with immune checkpoint inhibitors after EGFR‐TKIs in
EGFR
‐mutated lung cancer |
title_full_unstemmed | Treatment with immune checkpoint inhibitors after EGFR‐TKIs in
EGFR
‐mutated lung cancer |
title_short | Treatment with immune checkpoint inhibitors after EGFR‐TKIs in
EGFR
‐mutated lung cancer |
title_sort | treatment with immune checkpoint inhibitors after egfr‐tkis in
egfr
‐mutated lung cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807326/ https://www.ncbi.nlm.nih.gov/pubmed/34904383 http://dx.doi.org/10.1111/1759-7714.14267 |
work_keys_str_mv | AT itotakashi treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT nagashimahiromi treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT akiyamamasachika treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT utsumiyu treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT satohideomi treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT chibashinji treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT sugaimayu treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT ubekenji treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT moriyoshiaki treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT watanabekana treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT fukuharatatsuro treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer AT maemondomakoto treatmentwithimmunecheckpointinhibitorsafteregfrtkisinegfrmutatedlungcancer |